Bleb vascularity following post‐trabeculectomy subconjunctival bevacizumab: a pilot study

Background:  To determine whether postoperative subconjunctival bevacizumab significantly alters bleb vascularity.

[1]  S. Sengupta,et al.  Safety and Efficacy of Using Off-label Bevacizumab Versus Mitomycin C to Prevent Bleb Failure in a Single-site Phacotrabeculectomy by a Randomized Controlled Clinical Trial , 2012, Journal of glaucoma.

[2]  T. Żarnowski,et al.  Comparison of the use of 5‐fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year , 2012, Clinical & experimental ophthalmology.

[3]  N. Nassiri,et al.  Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. , 2012, American journal of ophthalmology.

[4]  K. Barton,et al.  Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery. , 2011, American journal of ophthalmology.

[5]  A. Mostafaei,et al.  Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma , 2011, Clinical ophthalmology.

[6]  E. O'Neill,et al.  Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. , 2010, Investigative ophthalmology & visual science.

[7]  K. Chalam,et al.  Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF , 2010, Molecular vision.

[8]  M. Kahook.  Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. , 2010, American journal of ophthalmology.

[9]  Michael B Horsley,et al.  Anti-VEGF therapy for glaucoma , 2010, Current opinion in ophthalmology.

[10]  J. Crowston,et al.  Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. , 2010, Investigative ophthalmology & visual science.

[11]  W. Spileers,et al.  Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. , 2009, Investigative ophthalmology & visual science.

[12]  A. Nugent,et al.  Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. , 2009, Investigative ophthalmology & visual science.

[13]  D. Venzon,et al.  The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors , 2009, Molecular Cancer Therapeutics.

[14]  R. Varma,et al.  Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. , 2009, Investigative ophthalmology & visual science.

[15]  D. Grimm,et al.  Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases. , 2009, Current vascular pharmacology.

[16]  G. Grana,et al.  A Review on Bevacizumab and Surgical Wound Healing: An Important Warning to All Surgeons , 2009, Annals of plastic surgery.

[17]  D. Grewal,et al.  Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. , 2008, Ophthalmology.

[18]  P. Herbison,et al.  Otago Glaucoma Surgery Outcome Study: long‐term results of 841 trabeculectomies , 2008, Clinical & experimental ophthalmology.

[19]  M. Coote,et al.  Vascular Changes After Intra-bleb Injection of Bevacizumab , 2008, Journal of glaucoma.

[20]  A. Wells,et al.  Medium-term outcomes of safe surgery system trabeculectomies , 2008, British Journal of Ophthalmology.

[21]  L. Cantor,et al.  Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. , 2008, Ophthalmology.

[22]  J. M. Purcell,et al.  Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy , 2008 .

[23]  D. August,et al.  “Spontaneous,” delayed colon and rectal anastomotic complications associated with bevacizumab therapy , 2008, Journal of surgical oncology.

[24]  I. Kohane,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[25]  M. Krasnow,et al.  Subconjunctival Injection(s) of Bevacizumab for Failing Filtering Blebs , 2007 .

[26]  W. Hauswirth,et al.  Bevacizumab Binding to Human Sclera Post Topical Application , 2006 .

[27]  J. Schuman,et al.  Needle bleb revision of encapsulated filtering bleb with bevacizumab. , 2006, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[28]  Betty Y. Y. Tam,et al.  VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[29]  H. Hurwitz,et al.  The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. , 2005, The Journal of surgical research.

[30]  C Bunce,et al.  A Pilot Study of a System for Grading of Drainage Blebs after Glaucoma Surgery , 2004, Journal of glaucoma.

[31]  M. Dana,et al.  Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. , 2004, Experimental eye research.

[32]  E. Paleolog,et al.  From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. , 2003, Birth defects research. Part C, Embryo today : reviews.

[33]  D. Bates,et al.  The Role of Vascular Endothelial Growth Factor in Wound Healing , 2003, The international journal of lower extremity wounds.

[34]  T. Żarnowski,et al.  Comparison of the use of 5-FU and bevacizumab in primary trabeculectomy: results at one year * , 2011 .

[35]  R. Schlingemann,et al.  Treatment of retinal diseases with VEGF antagonists. , 2009, Progress in brain research.

[36]  P. Khaw,et al.  Modulation of wound healing during and after glaucoma surgery. , 2008, Progress in brain research.